Navigation Links
Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development
Date:2/24/2009

Respected Researcher Provides Extensive Experience In Molecular Diagnostics

SALT LAKE CITY, Feb. 24 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostic technologies, announced today that Roberto A. Macina, Ph.D., has joined the executive management team as the company's new Vice President of Research and Development. Dr. Macina will report directly to Kenneth Ward, M.D., Chairman and Chief Scientific Officer for Axial Biotech.

"With over thirteen years of extensive professional experience in the fields of molecular biology, genomics, cancer research, and molecular diagnostics, Dr. Macina will be a valuable addition to Axial's management and research and development teams," said Dr. Ward. "Dr. Macina made a major contribution to the development of patent protected diagnostic products with high clinical value at diaDexus, Inc. His experience will greatly benefit Axial, as the company expands the indications for ScoliScore(TM) AIS Prognostic Test, the company's first DNA based assay."

Dr. Macina holds a B.S. degree in Biology and a Ph.D. in Biology from the University of Buenos Aires, Argentina. Dr. Macina completed his Post-Doctoral Fellowship at The Wistar Institute. Previous to joining Axial Biotech, Dr. Macina worked with the molecular diagnostics department at SmithKline Beecham in the discovery and characterization of novel genes differentially expressed in different cancers.

"Dr. Macina's decision to join Axial strengthens our company's position as a major player in the molecular diagnostic arena," said John Climaco, President and CEO. "He is joining our senior management team during a period of significant progress and advancement. I am confident that his experience, talent, and energy will very quickly make him a key factor in achieving rapid and efficient advancement of our promising diagnostic products."

"I am extremely excited and enthusiastic about the opportunity to contribute to the continuous growth of Axial Biotech, and to work with a unique combination of talented scientists teamed with skilled medical professionals and expert business specialists," stated Dr. Macina. "I am looking forward to leading the advancement of Axial Biotech's research and development, as the company moves forward with the commercialization of the ScoliScore prognostic test. Additionally, I anticipate that I will be able to effectively expedite the research and development efforts on Axial's pipeline of technologies and products for spinal disorders applications."

About Axial Biotech

Axial Biotech, Inc. is the leading developer of molecular diagnostics for common spinal diseases and disorders. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
2. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
3. Axial Biotech appoints new Vice President of Strategic Initiatives
4. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
5. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
6. DuPont Biotech Stewardship Program Gains External Certification
7. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
8. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
11. Yongye Biotechnology International to Expand its Network of Branded Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):